Enhancing blood vessel function with COMP-4 supplementation
The Effect of Daily COMP-4 Supplementation on Brachial Artery Flow Mediated Dilation and Cellular Senescence Markers in Young and Healthy Individuals
PHASE1; PHASE2 · University of California, Los Angeles · NCT05595915
This study is testing whether taking COMP-4 can improve blood vessel function in young adults to help prevent heart problems later in life.
Quick facts
| Phase | PHASE1; PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | All |
| Sponsor | University of California, Los Angeles (other) |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05595915 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of COMP-4 supplementation on flow-mediated dilation (FMD) in young adults, aiming to improve endothelial function and prevent cardiovascular diseases associated with aging and endothelial dysfunction. Participants aged 18-39 without a history of cardiovascular illnesses will be recruited to assess how COMP-4 influences nitric oxide production and vascular health. The study employs a combination of clinical assessments and interventions to evaluate the efficacy of COMP-4 in enhancing endothelial function.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy men and women aged 18-39 without any history of cardiovascular illnesses.
Not a fit: Patients outside the age range of 18-39 or those with a history of serious cardiovascular events may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to new preventive strategies for cardiovascular diseases in young adults.
How similar studies have performed: Other studies have shown promise in enhancing endothelial function through dietary supplements, but this specific approach with COMP-4 is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All men and women ages 18-39 will be offered the opportunity to participate in this study as long as they do not have a history of acute or chronic cardiovascular illnesses effecting flow mediated dilation. Exclusion Criteria: * Men and women with ages other than of 18-39 years of age; * Women who are currently pregnant; * Men and women with a history of serious cardiovascular events, those currently on blood pressure medications, and those with known allergies to any of the 4 components of COMP-4 (ginger, muira puama,Paullinia cupana, and L-citrulline)
Where this trial is running
Los Angeles, California
- UCLA — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Sriram V. Eleswarapu, MD PhD — University of California, Los Angeles
- Study coordinator: Sriram V. Eleswarapu, MD, PhD
- Email: seleswarapu@mednet.ucla.edu
- Phone: 3107943058
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Aging, Endothelial Dysfunction, Senescence, Flow Mediated Dilation, COMP-4, Endothelialfunction